The purpose of this study is to learn about the effects of the study drug tofacitinib for moderately to severely active ulcerative colitis (UC) in pediatric patients. Tofacitinib is a drug that affects the immune system. The immune system normally fights infection, but in diseases like UC, the immune system may be overactive or act incorrectly, leading to a chronic inflammation in the digestive tract (colon). Tofacitinib may be able to control disease activity, improve symptoms and keep up normal, every-day functions and activities.

The purpose of this study is to test the effectiveness of the drugs cabozantinib with nivolumab and ipilimumab in rare genitourinary (GU) cancers that have no standard treatment options.

This study is for prostate cancer patients taking hormone therapy treatments. Hormone therapy for prostate cancer is a treatment that can stop or reduce the male hormone, testosterone and is also called androgen deprivation therapy. Androgen deprivation therapy (ADT) or hormone therapy for prostate cancer includes medications to stop the body from producing testosterone or surgery to remove the testicles.
   

Rhabdomyosarcoma (RMS) is a type of cancer that occurs in the soft tissues of the body like the muscles. This study will compare the safety and effect of adding vinorelbine to vincristine, dactinomycin, and cyclophosphamide (VAC) for the treatment of patients with high risk rhabdomyosarcoma (RMS). High risk refers to cancer that is likely to recur (come back) after treatment or spread to other parts of the body.

This study is for male and female children, adolescents, and young adults under the age of 25 who have been diagnosed with Chronic Myeloid Leukemia (CML) that is in the earliest phase known as the chronic phase. Chronic phase means that the level of disease is very low and is often called molecular remission.  To keep the CML at this low level, people typically take a type of drug called a tyrosine kinase inhibitor (TKI), such as imatinib, dasatinib, and nilotinib every day.
   

The purpose of this study is to test the safety of a drug called M3814 (peposertib) in combination with a specific type of radiation therapy (hypofractionated radiation) in patients with locally advanced pancreatic cancer. This study will test different doses of M3814 to see which dose is safer for people when combined with hypofractionated radiation.

This study is for people who have stage III colon cancer that has been treated with surgery but has spread to some of the lymph nodes, or who have stage II or stage III colon cancer that has been treated with surgery and has a higher risk of returning based on positive circulating tumor DNA (ctDNA) results. ctDNA is DNA that has been released from tumor cells into the bloodstream. This DNA can be measured using a blood test.
   

This study is open to men and women over the age of 18 who have Kaposi Sarcoma (KS). Kaposi Sarcoma is a cancer related to a viral infection, known as the Kaposi sarcoma-associated herpesvirus, or KSHV.

This study aims to learn more about whether the experimental medication osimertinib (TAGRISSO) is more effective than placebo in participants with Epidermal Growth Factor Receptor (EGFR) mutated stage IA2 or IA3 non small cell lung cancer (NSCLC) after complete surgical removal of the tumor. 

This study is being done to determine the highest dose of AZD6738 that can safely be taken in combination with DS-8201a and what effect will this combination have on DNA repair mechanisms in advanced colorectal or gastroesophageal cancer.

There are two parts in this study, a dose escalation part, and a dose expansion part. The study doctor will tell each participant what part they are in.